Breaking News

Ionis Licenses NASH Drug to AstraZeneca

Advances IONIS-AZ6-2.5-LRx into development

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Ionis Pharmaceuticals, Inc. has licensed IONIS-AZ6-2.5-LRx, or AZD2693, to AstraZeneca following its advancement into development. IONIS-AZ6-2.5-LRx is designed to inhibit an undisclosed target to treat patients with nonalcoholic steatohepatitis (NASH). In conjunction with this milestone, AstraZeneca will pay a $30 million license fee to Ionis and will be responsible for further development and commercialization. Ionis is also eligible to receive as much as $300 million in additional development...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters